Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting…
Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present newin vitropharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that thein vitropharmacological profile of...
Nasdaq GlobeNewswire
23/10/2025
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an…
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall response rate in gynecological cancers at doses≥ 6.4mg/kgResponses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks’ novel antibody-drug conjugate platformDose optimization of ZW191 in ovarian cancer to initiate...
Nasdaq GlobeNewswire
23/10/2025
Oxurion Receives Transparency Notification from Atlas Special Opportunities II…
Leuven, BELGIUM – October 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on October 22, 2025, from Atlas Special Opportunities II…
Actusnews Wire
23/10/2025
World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis
IFPA's "Stop the Domino Effect" is urging policymakers, healthcare professionals and the public to recognize psoriasis for what it is: a serious, systemic, and life-changing disease that sets off a chain reaction of serious health conditions — from diabetes and cardiovascular disease to depression. The campaign highlights the urgent need for integrated care, early intervention and equal access to treatment worldwide. The organization calls on health authorities to include psoriasis in…
PR Newswire
23/10/2025
Czech Breakthrough in Medicine: H₂ Global Group Receives Regulatory Approval for…
From Japanese discovery to Czech clinical practice From Japanese discovery to Czech clinical practice The project is based on pioneering research by ProfessorShigeo Ohta, co-founder of H₂ Global Group and widely regarded as thefounding father of therapeutic hydrogen medicine. Professor Ohta personally transferred his European patent (EP 3701956 B1), titled"Prophylactic or Therapeutic Agent for Dementia,"to the Group. "Launching a clinical study that directly builds on...
PR Newswire
23/10/2025
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of…
Press Release The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in EuropeParis – October 23, 2025– EUROAPI officially launched its innovation programs today as part of the Health IPCEI (Important Project of Common European Interest), a European initiative aimed at strengthening pharmaceutical sovereignty. This project, called “Med4Cure,”...
Nasdaq GlobeNewswire
23/10/2025
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025…
Revenue at September 30, 2025Return to growth in Q3 20259-month revenue: €586.5 million, down 2.8% at CER 1and on a like-for-like basis 2, largely due to the fall in activity in FranceAn increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of Elucirem TMsales and good momentum on Lipiodol ® Confirmation of all financial targets for 2025Villepinte, October 23, 2025, 5.45 p.m.:Guerbet (FR0000032526 GBT), a global specialist in...
Nasdaq GlobeNewswire
23/10/2025
Medical Device Market Surges to USD 750 Billion by 2033, Propelled by 5.5% CAGR…
Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=482507 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=482507 Browse in-depth TOCon Medical Device Market202 – Pages 126 – Tables 37 – Figures Scope of The Medical Device Market Report Global Medical Device Market Overview Medical Device Market: Trends and Opportunities The global Medical Device Market is experiencing dynamic...
PR Newswire
23/10/2025
Avaz Joins the PRC-Saltillo Community, Expanding Global AAC Access and…
Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn, innovate, and grow together." Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn…
PR Newswire
23/10/2025
Orion and Abzena announce exclusive commercial license for Abzena’s antibody
ORION CORPORATION PRESS RELEASE23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibodyOrion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad...
Nasdaq GlobeNewswire
23/10/2025
Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer…
Click here to view the custom infographic of the Izotropic Corporation editorial. Clickhereto view the custom infographic of the Izotropic Corporationeditorial. The fusion of artificial intelligence (AI) and three-dimensional (3D) medical imaging is redefining diagnostic accuracy and efficiency. While traditional mammography has saved countless lives, its two-dimensional imaging format and need for physical compression limit visibility of internal structures, particularly in complex...
PR Newswire
23/10/2025
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for…
"This designation underscores the potential of our approach in Myelodysplastic Syndromes and supports our commitment to developing new treatment options for patients living with MDS," said David Bearss, PhD, Chief Executive Officer of Halia Therapeutics. "Ofirnoflast represents a first-in-class approach to modulating inflammasome biology, an upstream driver of inflammation, with the goal of restoring healthy bone marrow function." "This designation underscores the…
PR Newswire
23/10/2025
Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner®…
"We are very excited to have completed enrollment in this important trial, which we hope will bring us closer to being able to offer our patients comprehensive embolic protection for TAVR and other structural heart procedures," said Tamim Nazif, MD, Director of Clinical Research in Cardiology at Columbia University Irving Medical Center and Co-Principal Investigator for the Protect the Head to Head study. "The use of a full body embolic filter with debris capture and removal will…
PR Newswire
23/10/2025
Dr. Scott Leune to Bring His Practice Mastery Seminars to the UK
"For years, UK dentists have traveled to my seminars or joined my coaching programs remotely, and I knew it was time to bring these events to them," said Dr. Leune. "The UK dental market is underserved when it comes to the business of dentistry. Most dentists receive exceptional clinical training but very little guidance on how to build, grow, and sustain a profitable practice. My goal is to close that gap and provide UK dentists with the same strategies that have already…
PR Newswire
23/10/2025
TetraScience Launches Scientific AI Lighthouse Program with Takeda as Founding…
As a founding SAIL partner, Takeda will have first-mover access to TetraScience's full range of data and AI capabilities to accelerate AI-powered drug discovery, reduce CMC cycle times, enable in silico modeling, and increase scientist productivity through the use of agentic AI. The program is designed to enable biopharma organizations to bring more products to market at lower cost and risk by increasing productivity and improving candidate quality. As a founding SAIL partner, Takeda will…
PR Newswire
23/10/2025
Orion and Abzena Announce Exclusive Commercial License for Abzena's Antibody
Campbell Bunce, Chief Scientific Officer of Abzena, said, "We are delighted to have partnered with Orion on the design and development of our CHAb-designed mAb to support their extensive oncology-focused Research and Development pipeline. Using our uniquely integrated developability approach along with our streamlined AbZelectPRO™ CLD platform, we were able to design a de-risked lead antibody that offers Orion's program the best chances of success in the clinic." Campbell Bunce…
PR Newswire
23/10/2025
World's leading nutrition researchers discuss future lines of research on nuts…
The experts presented the latest research on nuts and dried fruit in relation to the main health challenges faced by the population, as well as new possible underlying mechanisms. The experts presented the latest research on nuts and dried fruit in relation to the main health challenges faced by the population, as well as new possible underlying mechanisms. During the event, an update of the NUTPOOL study, funded by the INC, was presented. This global initiative combines data from around one...
PR Newswire
23/10/2025
Amphista Therapeutics announces three key strategic leadership appointments to…
Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its ambition to bring its innovative Targeted Glue™ protein degraders to patients Cambridge, UK, 23 October 2025– Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the appointments of three senior leaders who...
Nasdaq GlobeNewswire
23/10/2025
TRIDENT, a dedicated stroke outcomes trial in patients with a history of…
GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placeboTrial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK, Boston, MA, 23 October 2025– George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announced that positive results from the investigator-initiated TRIDENT trial have been shared...
Nasdaq GlobeNewswire
23/10/2025
Alife Health Receives CE Mark Under European Medical Device Regulation for…
Embryo Predict was developed to address one of the most important, yet highly subjective, aspects of IVF: embryo grading. Traditional embryo assessment relies on manual observation of morphology, which can vary significantly between embryologists. Embryo Predict digitizes and standardizes this process, adding an additional layer of quality control and harnessing the power of AI to detect patterns of success from a vast dataset, providing data-driven insights that go beyond the limits of the…
PR Newswire
23/10/2025
ANTARES VISION GROUP TO SHOWCASE FULL-STACK TRACEABILITY SOLUTIONS AT THE 40th…
As a trusted partner in digitalization,Antares Vision Groupwill present its vision and solutions forend-to-end traceability, spanningserialization, aggregation, supply chain compliance, and hospital-level medication management. The company's approach demonstrates how GS1 standards allow each product to maintain aunique digital identitythroughout its lifecycle, enablingtransparency, regulatory compliance, and actionable dataat every step. "The true value of...
PR Newswire
23/10/2025
PCI Biotech update
Reference is made to the company’s announcements dated 18 thAugust 2025 and 25 thSeptember 2025, as well as the interim report for the first half of 2025 published on 29 thAugust 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future rely on continued interest under the...
Nasdaq GlobeNewswire
23/10/2025
RIMAN Officially Launches in London, Setting the Stage for European Market…
Formulated with heritage Korean ingredients such as RIMAN's patented plant, Giant BYoungPool™, and Jeju Lava Energy Water, RIMAN's products combine nature and science through advanced formulation technologies and a sustainability-focused vision. Formulated with heritage Korean ingredients such as RIMAN's patented plant, Giant BYoungPool™, and Jeju Lava Energy Water, RIMAN's products combine nature and science through advanced formulation technologies and a sustainability-focused vision...
PR Newswire
23/10/2025
Vantage Hemp Co. Strengthens Global Footprint with Initiation of European…
U.S. producer and WELDING GmbH & Co. KG partner to expand cannabinoid access in Europe Vantage Hemp Co. (“Vantage” or “the Company”), a globally accredited cannabinoid manufacturer, has initiated the submission process for its Certificate of Suitability (CEP) to the European Directorate for the Quality of Medicines (EDQM) and its Active Substance Master File (ASMF) to the European Medicines Agency (EMA). These applications place Vantage among the first global...
Nasdaq GlobeNewswire
23/10/2025
Altri Comunicati
